NEW YORK (GenomeWeb News) – Bayer Healthcare and the Broad Institute today announced a strategic alliance to jointly discover and develop therapeutic agents that target cancer genome alterations.

As part of the five-year deal, the partners will share their expertise on identifying and characterizing genes that are associated with cancer. They will also apply their screening platforms on compounds found in their libraries in order to identify those with potential as therapeutic agents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.